[PSY125] Market Access Trends In Rare Disease Approvals In Europe From 2005 To 2014
2015 Value in Health
Schultz, N.M. | Sarangpur, S. | Toumi, M. | Sherman, S. |
Over the past decade, the European Medicines Agency (EMA) has granted regulatory approval to over 75 rare disease therapies and acknowledged hundreds of pipeline compounds with rare disease regulatory designation. In Europe, market access for new technologies is predominantly dependent on regulatory and country-specific health technology assessments. Therefore, the purpose of this analysis was to examine how the impact of United Kingdom (UK) health policies affected the market access of rare disease technologies during 2005-2014.